Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Evry, France, May 10, 2016 -- Global Bioenergies (Alternext Paris: ALGBE) announces that the performance obtained in 2015 at laboratory scale has now been successfully reproduced in the pilot unit installed in Pomacle-Bazancourt (eastern France).
During the last fermentation-trial series, up to 74% of commercial target yield has been achieved. In addition, a high yield (higher than 65% of target) was maintained over several days. Strong robustness of the process is a key parameter for exploitation at larger scale.
Global Bioenergies' Isobutene process is the first-of-a-kind technology to directly produce a gas by fermentation. These results factually demonstrate that the process scales up very well at this stage. The demo plant, presently under construction in Germany, will allow running the technology at ton scale within months.
Marc Delcourt, co-founder and CEO of Global Bioenergies, concludes: "While our technology comes closer to commercial performances, the oil market is now swinging back. Innovative solutions to produce fuels and materials are more necessary today than ever. Global Bioenergies is getting prepared to play an important role in the transition of the energy and chemistry worlds toward technologies more friendly to the environment."
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates its industrial pilot, has begun the construction of its demo plant in Germany, and prepares the first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).
Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Contact
GLOBAL BIOENERGIES
Thomas BUHL
Head of Business Development
Phone: +33 (0)1 64 98 20 50
Email: [email protected]
PRESS RELEASE http://hugin.info/166909/R/2011379/744620.pdf
HUG#2011379
